Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure Neuroimaging and pathology

Published bySurya Kurnia Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure Neuroimaging and pathology"— Presentation transcript:

1 Figure Neuroimaging and pathology
Neuroimaging and pathology (A) Pretreatment T1-weighted MRI shows curvilinear, punctate gadolinium contrast enhancement, predominantly in the pons. (B) Pretreatment T2-weighted MRI shows multiple T2 hyperintense lesions in the brainstem. (C) Posttreatment T1-weighted MRI shows resolution of previously enhancing areas of the brainstem. (D) Posttreatment T2-weighted MRI shows faint, patchy T2 hyperintensities in the areas of previous contrast enhancement in the pons. (E, F) Low- and high-power images of the H&E-stained slides (original magnification ×100 and ×200, respectively) of the left parietal brain biopsy showing with prominent small perivascular lymphocytes and more diffuse infiltration by macrophages. (G) Most of the lymphocytes label as CD3+ T cells (original magnification ×200). (H) Many of these T cells express CD8 (original magnification ×400). (I) There is a paucity of CD20+ staining B cells in the sample (original magnification ×200; the same region shown in G). (J) CD68 confirms the presence of numerous foamy macrophages (original magnification ×200). Veronica P. Cipriani et al. Neurol Neuroimmunol Neuroinflamm 2018;5:e448 Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology

Download ppt "Figure Neuroimaging and pathology"

Similar presentations

Figure 1 Box plot of the venous diameter in lesions

Figure 1 Box plot of the venous diameter in lesions
Figure 1 Regional changes in FA values

Figure 1 Regional changes in FA values
Figure 1 Brain MRI findings in the present case

Figure 1 Brain MRI findings in the present case
Figure MRI of anti-MOG-IgG–associated myelitis

Figure MRI of anti-MOG-IgG–associated myelitis
Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.

Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.
Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1 Coronal MRI images showing the evolution of white.

Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1 Coronal MRI images showing the evolution of white.
Figure Facial photograph during headache attack and brain and upper cervical cord MRI Facial photograph during headache attack and brain and upper cervical.

Figure Facial photograph during headache attack and brain and upper cervical cord MRI Facial photograph during headache attack and brain and upper cervical.
Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.

Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.
Figure 1 Spine MRI, sagittal and axial views of patients with idiopathic transverse myelitis with VPS37A mutations Spine MRI, sagittal and axial views.

Figure 1 Spine MRI, sagittal and axial views of patients with idiopathic transverse myelitis with VPS37A mutations Spine MRI, sagittal and axial views.
Figure 3 Example of venous narrowing

Figure 3 Example of venous narrowing
Figure 2 Immunopathologic analysis of all 3 Rasmussen encephalitis cases Immunopathologic analysis of all 3 Rasmussen encephalitis cases (A) Perivascular.

Figure 2 Immunopathologic analysis of all 3 Rasmussen encephalitis cases Immunopathologic analysis of all 3 Rasmussen encephalitis cases (A) Perivascular.
Figure Muscle biopsy of the left biceps showing the characteristic pathologic findings in BCIM Muscle biopsy of the left biceps showing the characteristic.

Figure Muscle biopsy of the left biceps showing the characteristic pathologic findings in BCIM Muscle biopsy of the left biceps showing the characteristic.
Figure Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab Immune checkpoint inhibitor–induced encephalitis before.

Figure Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab Immune checkpoint inhibitor–induced encephalitis before.
Figure 3 Age, pretreatment, sex, and leukopenia do not influence CD19+ cell repopulation Age, pretreatment, sex, and leukopenia do not influence CD19+

Figure 3 Age, pretreatment, sex, and leukopenia do not influence CD19+ cell repopulation Age, pretreatment, sex, and leukopenia do not influence CD19+
Figure 1 Histopathologic features of a chronic active and a chronic plaque in the MS brain Histopathologic features of a chronic active and a chronic plaque.

Figure 1 Histopathologic features of a chronic active and a chronic plaque in the MS brain Histopathologic features of a chronic active and a chronic plaque.
Figure Radiographic and histopathologic findings (A) Brain MRI at presentation shows multiple areas of T2 hyperintensity in the mesial temporal lobes,

Figure Radiographic and histopathologic findings (A) Brain MRI at presentation shows multiple areas of T2 hyperintensity in the mesial temporal lobes,
Figure Clinical presentation of daclizumab side effects with skin rash and meningoencephalomyelitis Clinical presentation of daclizumab side effects with.

Figure Clinical presentation of daclizumab side effects with skin rash and meningoencephalomyelitis Clinical presentation of daclizumab side effects with.
Figure 4 Detection of EBER+ cells in MS and control brains by in situ hybridization Detection of EBER+ cells in MS and control brains by in situ hybridization.

Figure 4 Detection of EBER+ cells in MS and control brains by in situ hybridization Detection of EBER+ cells in MS and control brains by in situ hybridization.
Figure Brain MRI and biopsy specimens from the pontine lesion

Figure Brain MRI and biopsy specimens from the pontine lesion
Figure 1 Quantitative spinal cord MRI maps and segmentations

Figure 1 Quantitative spinal cord MRI maps and segmentations

Similar presentations

Ads by Google